Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Carglumic Acid (Ureidoglutaric acid) is an orphan drug used to treat hyperammonemia in patients with N-acetyl glutamate synthase absence. This rare hereditary disease results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and lead to neurologic problems, coma, cerebral edema, and death. Carglumic acid was approved by the U.S. FDA on 18 March 2010.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
200 mg | In stock | $ 48.00 | |
500 mg | In stock | $ 89.00 | |
1 g | In stock | $ 119.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 55.00 |
Description | Carglumic Acid (Ureidoglutaric acid) is an orphan drug used to treat hyperammonemia in patients with N-acetyl glutamate synthase absence. This rare hereditary disease results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and lead to neurologic problems, coma, cerebral edema, and death. Carglumic acid was approved by the U.S. FDA on 18 March 2010. |
Synonyms | Carbaglu, N-Carbamylglutamate, N-Carbamyl-L-glutamic acid, Carbamylglutamic acid, Carbamino-L-glutamic acid, Ureidoglutaric acid |
Molecular Weight | 190.15 |
Formula | C6H10N2O5 |
CAS No. | 1188-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (236.66 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Carglumic Acid 1188-38-1 Others Carbaglu N-Carbamylglutamate N-Carbamyl-L-glutamic acid inhibit Carbamylglutamic acid Inhibitor Carbamino-L-glutamic acid Ureidoglutaric acid inhibitor